22Feb 2025
CDC Risk Factors in IBD Patients Treated with Vedolizumab

CDC Risk Factors in IBD Patients Treated with Vedolizumab

The incidence of C. difficile colonization (CDC) after Vedolizumab (VDZ) treatment in IBD patients was 6.2%. Age >40 years and ulcerative colitis (UC) were identified as significant risk factors. A total of 454 patients were analyzed, with 28 developing CDC, including 23 with ulcerative colitis. The incidence of C. difficile infection (CDI) was 1.1%, and all patients continued VDZ treatment post-antibiotic therapy.

  • #gastroenterology

Like

Save

Share